Cargando…

Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report

BACKGROUND: Renal clear cell carcinoma (RCC) is a malignant tumor of the genitourinary system with a predilection for males. The most common metastatic sites are the lung, liver, lymph nodes, contralateral kidney or adrenal gland, however, skin metastasis has only been seen in 1.0%-3.3% of cases. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Shuai, Xu, Yang-Chun, Zhang, Yuan-Chen, Xia, Jian-Xin, Mou, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044962/
https://www.ncbi.nlm.nih.gov/pubmed/36998957
http://dx.doi.org/10.12998/wjcc.v11.i9.2104
_version_ 1784913477309038592
author Dong, Shuai
Xu, Yang-Chun
Zhang, Yuan-Chen
Xia, Jian-Xin
Mou, Yan
author_facet Dong, Shuai
Xu, Yang-Chun
Zhang, Yuan-Chen
Xia, Jian-Xin
Mou, Yan
author_sort Dong, Shuai
collection PubMed
description BACKGROUND: Renal clear cell carcinoma (RCC) is a malignant tumor of the genitourinary system with a predilection for males. The most common metastatic sites are the lung, liver, lymph nodes, contralateral kidney or adrenal gland, however, skin metastasis has only been seen in 1.0%-3.3% of cases. The most common site of skin metastasis is the scalp, and metastasis to the nasal ala region is rare. CASE SUMMARY: A 55-year-old man with clear cell carcinoma of the left kidney was treated with pembrolizumab and axitinib for half a year after surgery and was found to have a red mass on his right nasal ala for 3 mo. The skin lesion of the patient grew rapidly to the size of 2.0 cm × 2.0 cm × 1.2 cm after discontinuation of targeted drug therapy due to the coronavirus disease 2019 epidemic. The patient was finally diagnosed with skin metastasis of RCC in our hospital. The patient refused to undergo surgical resection and the tumor shrank rapidly after resuming target therapy for 2 wk. CONCLUSION: It is rare for an RCC to metastasize to the skin of the nasal ala region. The tumor size change of this patient before and after treatment with targeted drugs shows the effectiveness of combination therapy for skin metastasis.
format Online
Article
Text
id pubmed-10044962
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-100449622023-03-29 Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report Dong, Shuai Xu, Yang-Chun Zhang, Yuan-Chen Xia, Jian-Xin Mou, Yan World J Clin Cases Case Report BACKGROUND: Renal clear cell carcinoma (RCC) is a malignant tumor of the genitourinary system with a predilection for males. The most common metastatic sites are the lung, liver, lymph nodes, contralateral kidney or adrenal gland, however, skin metastasis has only been seen in 1.0%-3.3% of cases. The most common site of skin metastasis is the scalp, and metastasis to the nasal ala region is rare. CASE SUMMARY: A 55-year-old man with clear cell carcinoma of the left kidney was treated with pembrolizumab and axitinib for half a year after surgery and was found to have a red mass on his right nasal ala for 3 mo. The skin lesion of the patient grew rapidly to the size of 2.0 cm × 2.0 cm × 1.2 cm after discontinuation of targeted drug therapy due to the coronavirus disease 2019 epidemic. The patient was finally diagnosed with skin metastasis of RCC in our hospital. The patient refused to undergo surgical resection and the tumor shrank rapidly after resuming target therapy for 2 wk. CONCLUSION: It is rare for an RCC to metastasize to the skin of the nasal ala region. The tumor size change of this patient before and after treatment with targeted drugs shows the effectiveness of combination therapy for skin metastasis. Baishideng Publishing Group Inc 2023-03-26 2023-03-26 /pmc/articles/PMC10044962/ /pubmed/36998957 http://dx.doi.org/10.12998/wjcc.v11.i9.2104 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Case Report
Dong, Shuai
Xu, Yang-Chun
Zhang, Yuan-Chen
Xia, Jian-Xin
Mou, Yan
Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report
title Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report
title_full Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report
title_fullStr Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report
title_full_unstemmed Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report
title_short Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report
title_sort pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044962/
https://www.ncbi.nlm.nih.gov/pubmed/36998957
http://dx.doi.org/10.12998/wjcc.v11.i9.2104
work_keys_str_mv AT dongshuai pembrolizumabcombinedwithaxitinibinthetreatmentofskinmetastasisofrenalclearcellcarcinomatonasalalaacasereport
AT xuyangchun pembrolizumabcombinedwithaxitinibinthetreatmentofskinmetastasisofrenalclearcellcarcinomatonasalalaacasereport
AT zhangyuanchen pembrolizumabcombinedwithaxitinibinthetreatmentofskinmetastasisofrenalclearcellcarcinomatonasalalaacasereport
AT xiajianxin pembrolizumabcombinedwithaxitinibinthetreatmentofskinmetastasisofrenalclearcellcarcinomatonasalalaacasereport
AT mouyan pembrolizumabcombinedwithaxitinibinthetreatmentofskinmetastasisofrenalclearcellcarcinomatonasalalaacasereport